<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00052468</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000258429</org_study_id>
    <secondary_id>AGO-OVAR9</secondary_id>
    <secondary_id>NORDIC-AGO-OVAR-9</secondary_id>
    <secondary_id>GERCOR-AGO-OVAR-9</secondary_id>
    <secondary_id>EU-20241</secondary_id>
    <nct_id>NCT00052468</nct_id>
  </id_info>
  <brief_title>Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer</brief_title>
  <acronym>AGO-OVAR9</acronym>
  <official_title>A Multi-National Randomized Phase-III GCIG Intergroup-Study Comparing 1st-line Chemotherapy With Gemcitabine/Paclitaxel/Carboplatin vs Paclitaxel/Carboplatin In Previously Untreated Patients With Epithelial Ovarian Cancer FIGO Stages I-IV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AGO Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nordic Society of Gynaecological Oncology - Clinical Trials Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GERCOR - Multidisciplinary Oncology Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AGO Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells. It is not&#xD;
      yet known whether carboplatin and paclitaxel combined with gemcitabine is more effective than&#xD;
      carboplatin and paclitaxel alone in treating ovarian epithelial or fallopian tube cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying carboplatin and paclitaxel combined with&#xD;
      gemcitabine to see how well it works compared to paclitaxel and carboplatin alone in treating&#xD;
      patients who have undergone surgery for ovarian epithelial or fallopian tube cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare overall survival in patients with stage I-IV ovarian epithelial or fallopian&#xD;
           tube cancer treated with adjuvant carboplatin and paclitaxel with or without&#xD;
           gemcitabine.&#xD;
&#xD;
        -  Compare response rates, progression-free survival, and duration of response in patients&#xD;
           treated with these regimens.&#xD;
&#xD;
        -  Compare toxic effects of these regimens in these patients.&#xD;
&#xD;
        -  Compare quality of life of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, open-label, controlled, multicenter study. Patients are&#xD;
      stratified according to FIGO stage (I-IIA vs IIB-IIIC and tumor no greater than 10 mm vs&#xD;
      IIB-IIIC and tumor greater than 10 mm or IV), plan for interval surgical debulking (yes vs&#xD;
      no), and participating center. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive carboplatin IV over 30-60 minutes and paclitaxel IV over 3 hours&#xD;
           on day 1 and gemcitabine IV over 30-60 minutes on days 1 and 8.&#xD;
&#xD;
        -  Arm II: Patients receive carboplatin and paclitaxel as in arm I. Treatment in both arms&#xD;
           repeats every 21 days for 6 to 10 courses in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
      Some patients undergo interval debulking surgery.&#xD;
&#xD;
      Quality of life is assessed at baseline, after courses 3 and 6, and then at 3, 6, and 12&#xD;
      months after completion of study.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years, every 6 months for up to 5 years, and then&#xD;
      annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 1,716 patients (858 per treatment arm) will be accrued for this&#xD;
      study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Whole Study Period</time_frame>
    <description>Survival time is calculated from the date of enrollment into the study until the date of death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Whole Study Period</time_frame>
    <description>The progression-free survival is calculated for all patients from the date of enrollment until the date of first progressive disease or death, whichever occurs first</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Whole Study Period</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1742</enrollment>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>TCG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel 175 mg/m2 day 1, Carboplatin AUC 5 day 1, Gemcitabine 800 mg/m2 day 1 + 8, q 21 days / 6 - 10 courses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel 175 mg/m2 day 1, Carboplatin AUC 5 day 1, q 21 days / 6 - 10 courses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TCG</intervention_name>
    <arm_group_label>TCG</arm_group_label>
    <other_name>Paclitaxel/Carboplatin/Gemcitabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TC</intervention_name>
    <arm_group_label>TC</arm_group_label>
    <other_name>Paclitaxel/Carboplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of one of the following:&#xD;
&#xD;
               -  Ovarian epithelial cancer&#xD;
&#xD;
                    -  FIGO stage IA/B G3, IC-IV&#xD;
&#xD;
               -  Fallopian tube cancer&#xD;
&#xD;
               -  Extra-ovarian papillary serous tumor&#xD;
&#xD;
          -  The following are ineligible:&#xD;
&#xD;
               -  Low malignant-potential ovarian tumors (borderline tumors)&#xD;
&#xD;
               -  Non-epithelial ovarian tumors&#xD;
&#xD;
               -  Mixed Mullerian tumors&#xD;
&#xD;
          -  Must have had definitive surgery within the past 6 weeks&#xD;
&#xD;
          -  No symptomatic brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 6 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 3,000/mm^3 OR&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 10 mg/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 2 times upper limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Glomerular filtration rate at least 50 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
          -  No prior atrial or ventricular arrhythmias&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No prior seizures or central nervous system disorder&#xD;
&#xD;
          -  No prior severe hypersensitivity reaction to products containing Cremophor EL (e.g.,&#xD;
             cyclosporine or vitamin K)&#xD;
&#xD;
          -  No known hypersensitivity to compounds chemically related to carboplatin, gemcitabine,&#xD;
             or paclitaxel&#xD;
&#xD;
          -  No preexisting motor or sensory neuropathy greater than grade 1&#xD;
&#xD;
          -  No other malignancy within the past 5 years except:&#xD;
&#xD;
               -  Malignancies cured by surgery alone&#xD;
&#xD;
               -  Carcinoma in situ of the cervix&#xD;
&#xD;
               -  Adequately treated basal cell skin cancer&#xD;
&#xD;
          -  No complete bowel obstruction&#xD;
&#xD;
          -  No other concurrent severe medical condition that would preclude study participation&#xD;
&#xD;
          -  No dementia or significantly altered mental status that would preclude study&#xD;
             participation&#xD;
&#xD;
          -  No concurrent severe active infection&#xD;
&#xD;
          -  Geographically accessible for treatment and follow-up&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent hormonal therapy except:&#xD;
&#xD;
               -  Hormone replacement therapy&#xD;
&#xD;
               -  Antiemetic steroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent antineoplastic agents&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No other concurrent clinical trial enrollment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas du Bois, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Dr. Horst-Schmidt-Kliniken</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J. Herrstedt</last_name>
    <role>Study Chair</role>
    <affiliation>Copenhagen County Herlev University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>E. Pujade-Lauraine, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hotel Dieu de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herlev Hospital - University Hospital of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu de Paris</name>
      <address>
        <city>Paris</city>
        <zip>75181</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentralkrankenhaus</name>
      <address>
        <city>Bremen</city>
        <zip>D-28205</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus</name>
      <address>
        <city>Dusseldorf</city>
        <zip>DOH-40217</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>D-45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtische Kliniken Frankfurt am Main - Hoechst</name>
      <address>
        <city>Frankfurt</city>
        <zip>D-65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frauenklinik der MHH</name>
      <address>
        <city>Hannover</city>
        <zip>30659</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vincentius Krankenhaus</name>
      <address>
        <city>Karlsruhe</city>
        <zip>D-76137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Schleswig-Holstein - Kiel Campus</name>
      <address>
        <city>Kiel</city>
        <zip>D-24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinkum Magdeburg der Otto-von-Guericke-Universitaet Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39108</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik fuer Frauenheilkunde und Geburtshilfe - Universitaetsklinikum Muenster</name>
      <address>
        <city>Muenster</city>
        <zip>D-48129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Grosshadern der Ludwig-Maximilians Universitaet Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts Der Isar - Technische Universitaet Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>D-81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaet Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>D-89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Horst-Schmidt-Kliniken</name>
      <address>
        <city>Wiesbaden</city>
        <zip>D-65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norwegian Radium Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>N-0310</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Norway</country>
  </location_countries>
  <results_reference>
    <citation>du Bois A, Herrstedt J, Hardy-Bessard AC, MÃ¼ller HH, Harter P, Kristensen G, Joly F, Huober J, Avall-Lundqvist E, Weber B, Kurzeder C, Jelic S, Pujade-Lauraine E, Burges A, Pfisterer J, Gropp M, Staehle A, Wimberger P, Jackisch C, Sehouli J. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol. 2010 Sep 20;28(27):4162-9. doi: 10.1200/JCO.2009.27.4696. Epub 2010 Aug 23.</citation>
    <PMID>20733132</PMID>
  </results_reference>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>January 24, 2003</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 24, 2014</last_update_submitted>
  <last_update_submitted_qc>June 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I ovarian epithelial cancer</keyword>
  <keyword>stage II ovarian epithelial cancer</keyword>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>fallopian tube cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

